|Articles|May 1, 2013
- Pharmaceutical Executive-05-01-2013
- Volume 0
- Issue 0
PE, May 2013 Cover Image
S
Advertisement
Cover
Articles in this issue
over 12 years ago
Is That VBP on the Horizon, or a Mirage?over 12 years ago
Country Report: Austriaover 12 years ago
The Friendly Persuasion — An Interview with Fred Hassanover 12 years ago
Whistling Past the Graveyardover 12 years ago
The Patent Black Labelover 12 years ago
It's Time For a Code of Ethics in Patient Educationover 12 years ago
The Health Information Advantageover 12 years ago
Generic Drug Gains and GrumblesNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Trending on PharmExec
1
Report: Richard Pazdur Out as Director of CDER
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
4
Regeneron Announces $150 Million Collaboration with Tessera Therapeutics to Develop Gene Editing Therapy
5
